Introduction of COVID-19 Neutralizing Antibody

Boditech Med is delighted to share the news that we launched the new product for the detection of COVID-19 neutralizing antibody in humans who inoculated with the COVID-19 vaccine or were infected with COVID-19. The AFIAS COVID-19 nAb test kit is a simple medical reagent that identifies the presence of neutralizing antibodies, which prevents RBD of the spike protein of SARS-CoV-2 virus from attaching to the receptor protein ACE-2 (Angiotensin-converting enzyme-2) on the surface of normal cells in humans.

Features:

1. Speed of verification of experimental results: Results can be verified within 20 minutes compared to the standard test method (Plaque Reduction Neutralization Test, PRNT), which takes about one week to prepare and verify experimental results.
2. Convenience of the experimenter: Measurement and output results automatically when a small amount of patient sample (whole blood, serum or plasma) is inserted without unnecessary preparation.
3. Experimental Safety: No facilities such as Bio-Safety level-3 (BL3) are required as the live virus is not used.

With the easy-to-use AFIAS system, we believe that AFIAS COVID-19 nAb will help for the evaluation of immunity after infection or vaccination of COVID-19.

Neutralizing antibodies are antibodies that inhibit virus proliferation by blocking virus penetration into cells. The neutralizing antibody diagnostic kit is a product that checks whether the neutralizing antibody produced by vaccination or infection works properly. A company official said, "Corona 19 virus is highly infectious, so it is necessary to continuously check whether neutralizing antibodies are normally formed even after vaccination, and the demand for kits is expected to increase sharply after 2021 when the vaccine is supplied."